Tang Capital Management CGEM Position
Exited9-Fund ConvergenceTang Capital Management exited their position in Cullinan Therapeutics, Inc. (CGEM) in Q4 2025, after holding the stock for 12 quarters.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
CGEM is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 15.9% of float with 9.5 days to cover, indicating significant bearish positioning against the stock.
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Full company profile →Short Interest
15.9%
9.5 days to cover
Tang Capital Management CGEM Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Exited | 0 | -1,121,138 | $0 |
| Q3 2025 | Held | 1,121,138 | — | $6.6M |
| Q2 2025 | Held | 1,121,138 | — | $8.4M |
| Q1 2025 | Increased | 1,121,138 | +200,000 | $8.5M |
| Q4 2024 | Held | 921,138 | — | $11.2M |
| Q3 2024 | Held | 921,138 | — | $15.4M |
| Q2 2024 | Increased | 921,138 | +350,000 | $16.1M |
| Q1 2024 | Decreased | 571,138 | -200,000 | $9.7M |
| Q4 2023 | Increased | 771,138 | +150,000 | $7.9M |
| Q3 2023 | Increased | 621,138 | +171,138 | $5.6M |
| Q2 2023 | Decreased | 450,000 | -50,000 | $4.8M |
| Q1 2023 | New | 500,000 | +500,000 | $5.1M |
Frequently Asked Questions
Does Tang Capital Management own CGEM?
No. Tang Capital Management exited their position in Cullinan Therapeutics, Inc. (CGEM) in Q4 2025. They previously held the stock for 12 quarters.
How many hedge funds own CGEM?
9 specialist biotech hedge funds currently hold CGEM, including BVF Partners, Deerfield Management, RTW Investments and 6 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy CGEM?
Tang Capital Management's position in CGEM was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's CGEM position increasing or decreasing?
Tang Capital Management completely exited their CGEM position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CGEMCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →